Feedback

Time-varying cost-effectiveness analysis of sodium-glucose cotransporter-2 inhibitors in Chinese patients with heart failure and reduced ejection fraction: A microsimulation of the real-world population

Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
Zou, Xinyu;
Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
He, Xingchen;
Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
Shi, Qingyang;
Affiliation
Department of Cardiology ,West China Hospital of Sichuan University ,Chengdu ,China
Wang, Si;
Affiliation
Department of Informatics ,West China Hospital of Sichuan University ,Chengdu ,China
Li, Nan;
Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
Zhou, Yiling;
Affiliation
West China School of Pharmacy ,Sichuan University ,Chengdu ,China
Hu, Ming;
Affiliation
Business School ,Sichuan University ,Chengdu ,China
Luo, Li;
Affiliation
School of Business and Management ,The Hong Kong University of Science and Technology ,Hong Kong ,Hong Kong SAR, China
Shen, Yiwen;
Affiliation
Department of Cardiology ,West China Hospital of Sichuan University ,Chengdu ,China
Zhu, Ye;
Affiliation
Division of Molecular and Clinical Medicine ,Ninewells Hospital ,University of Dundee ,Dundee ,United Kingdom
Lang, Chim C.;
Affiliation
Department of Hypertension and Endocrinology ,Center for Hypertension and Metabolic Diseases ,Daping Hospital ,Army Medical University ,Chongqing ,China
Zhu, Zhiming;
Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
Tian, Haoming;
Affiliation
Department of Endocrinology and Metabolism ,MAGIC China Center ,West China Hospital of Sichuan University ,Chengdu ,China
Li, Sheyu

Objective Sodium-glucose cotransporter-2 (SGLT2) inhibitors showed time-varying effects in heart failure and reduced ejection fraction (HFrEF), but corresponding cost-effectiveness in different timeframes remained poorly understood. This study estimated the time-varying cost-effectiveness of SGLT2 inhibitors in HFrEF from the perspective of the Chinese healthcare system. Methods Based on real-world individual patient data, a 2-year microsimulation model was constructed to evaluate the cost-effectiveness of adding SGLT2 inhibitors to standard therapy compared with standard therapy alone among patients with HFrEF. A published prediction model informed transition probabilities for all-cause death and hospitalization for heart failure. The time-varying effects of SGLT2 inhibitors, medical costs, and utility values were derived from the published literature. Scenario analyses in different timeframes were conducted to assess the trend of cost-effectiveness over time. Results Compared with standard therapy alone, SGLT2 inhibitors plus standard therapy were found cost-effective at a willingness‐to‐pay (WTP) threshold of $12,741 per quality‐adjusted life year (QALY) gained in 2 years. The incremental cost-effectiveness ratio (ICER) decreased from $12,346.07/QALY at 0.5 years to $9,355.66/QALY at 2 years. One-direction sensitivity analysis demonstrated that the cost-effectiveness of SGLT2 inhibitors was most sensitive to the cost of SGLT2 inhibitors, the cost of hospitalization for heart failure, the cost of standard therapy for heart failure, and the baseline risks of all-cause death and hospitalization for heart failure. Probabilistic sensitivity analysis proved the robustness of the results. Conclusion Adding SGLT2 inhibitors to standard therapy was found to be cost-effective in Chinese patients with HFrEF. Longer treatment appeared to be more economically favorable, but further explorations are warranted.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2025 Zou, He, Shi, Wang, Li, Zhou, Hu, Luo, Shen, Zhu, Lang, Zhu, Tian and Li.

Use and reproduction: